home All News open_in_new Full Article

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD) In preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today […]


today 9 h. ago attach_file Other

attach_file Other
attach_file Other
attach_file Culture
attach_file Other
attach_file Other
attach_file Culture
attach_file Other
attach_file Economics
attach_file Economics
attach_file Transport
attach_file Other
attach_file Politics
attach_file Culture
attach_file Events
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Events


ID: 2783021427
Add Watch Country

arrow_drop_down